Sermorelin

Think of it like a respected old prescription medicine that quietly went out of print because it stopped selling, not because it failed, and has since been photocopied and hawked on a street corner under a new cover story. The original chapters (testing children's pituitaries, treating kids who weren't growing) were well written and peer-reviewed. The new marketing blurb on the back the turn-back-the-clock-for-adults part was largely made up by whoever is now selling the photocopies.

Sermorelin is a GHRH-receptor agonist. It mimics endogenous growth-hormone-releasing hormone at somatotroph cells in the anterior pituitary, activating Gs-coupled cAMP signalling to stimulate synthesis and pulsatile secretion of growth hormone, which in turn raises hepatic IGF-1. Because it acts upstream of the pituitary and leaves the body's somatostatin/IGF-1 negative feedback intact, the resulting GH release is comparatively physiological and self-limiting, rather than the fixed feedback-bypassing exposure delivered by injecting GH directly. It has a very short circulating half-life (on the order of minutes) due to rapid enzymatic degradation. The general route of administration is subcutaneous injection.

Research contexts. Not proven uses, and not recommendations.

Substantial for its historical licensed indications, weak for what it is sold for today. Sermorelin was a fully approved US medicine (Geref, approved 1997) as a diagnostic test of pituitary GH reserve and for treating growth hormone deficiency in children, where controlled paediatric studies showed increased GH secretion and improved height velocity. That is real, regulator-grade human evidence and is why this scores higher than a typical research peptide. The modern use case driving grey-market demand boosting GH/IGF-1 in healthy or ageing adults for vitality, muscle, fat loss, sleep and longevity rests on small, old or extrapolated data and lacks robust modern randomised trials demonstrating meaningful clinical benefit or long-term safety. The product was discontinued in 2008 and FDA approval was withdrawn effective 2009. The FDA confirmed in a 2013 Federal Register notice that this was not for reasons of safety or effectiveness.

• !No current UK (MHRA) marketing authorisation and no current FDA approval. The licensed product was discontinued in 2008 and approval withdrawn in 2009. Anything sold now is unlicensed.
• !Grey-market vials sold as research chemicals or not for human consumption carry no guarantee of identity, purity, dose accuracy or sterility. Injecting unregulated product carries infection and contamination risk.
• !Raising GH/IGF-1 is not consequence-free. Recognised risks of GH-axis stimulation include fluid retention, joint pain, carpal tunnel symptoms, impaired glucose tolerance and insulin resistance. There is a theoretical concern about promoting growth of existing malignancies, warranting caution with any cancer history or active disease.
• !Evidence for the popular adult anti-ageing and body-composition claims is thin and dated. Marketing routinely overstates benefit by borrowing from the paediatric-deficiency and diagnostic literature.
• !Even in its legitimate diagnostic role it cannot distinguish GH deficiency of hypothalamic origin.
• !Use without endocrine supervision means no monitoring of glucose, IGF-1 or adverse effects.
• !Potential for misuse in sport: stimulating endogenous GH falls under anti-doping prohibitions. WADA prohibits GH secretagogues and GHRH analogues at all times.

Not a licensed UK medicine. Sermorelin has no current MHRA marketing authorisation and does not appear in the BNF. The historical Geref/Geref Diagnostic products are no longer marketed. The US approval was withdrawn in 2009 following discontinuation in 2008, for commercial rather than safety reasons. In the UK it is encountered only as an unlicensed substance sold through research chemical suppliers, typically labelled not for human consumption to sidestep medicines regulation. Supplying it for human medicinal use without authorisation would breach the Human Medicines Regulations 2012. It is not a controlled drug under the Misuse of Drugs Act, but it is also not legally available as an off-the-shelf treatment outside an authorised or properly governed unlicensed-medicine (specials) route under prescriber responsibility.

1. 01
   Determination That GEREF (Sermorelin Acetate) Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, US FDA, Federal Register (2013-04827) (2013)

   Official confirmation that the licensed sermorelin (Geref) products were discontinued/withdrawn for commercial, not safety or efficacy, reasons.

2. 02
   Growth hormone secretagogues: history, mechanism of action, and clinical development — Ishida J, et al., JCSM Rapid Communications (Wiley), vol 3, 25-37 (2020)

   Peer-reviewed review placing sermorelin within the broader class of GHRH analogues and GH secretagogues and summarising their clinical development.

3. 03
   Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (review of GHRH(1-29) pharmacology and clinical rationale), Review literature indexed on PubMed (2010)

   Descriptive PubMed search given rather than a guessed identifier discusses GHRH(1-29) mechanism and the rationale (and limits) of adult use.

4. 04
   Sermorelin (overview of structure, GHRH(1-29) pharmacology and Geref approval/withdrawal history), Wikipedia / DrugBank summary (2024)

   Convenience summary only, not a primary source: structure, mechanism, 1997 paediatric GHD approval and 2008/2009 discontinuation/withdrawal.